MacroGenics Pauses Lorigerlimab Trial Enrollment Following FDA Partial Hold

Key Facts

1The FDA has placed a partial clinical hold on the LINNET study of lorigerlimab.

2MacroGenics announced the pausing of enrollment for new participants in the study targeting gynecologic cancer.

MacroGenics (MGNX) has announced a pause in the enrollment of new participants for its LINNET clinical trial. This decision follows a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding the study of lorigerlimab. The trial specifically targets patients with gynecologic cancer, and the regulatory intervention highlights potential safety concerns or the need for additional data. Clinical holds are viewed as significant setbacks for biotechnology firms, as they often delay development timelines and increase operational uncertainty. Investors are closely monitoring the company's response to the FDA's requirements to resume the study. Shares of MacroGenics are expected to face pressure as the market digests the implications of this regulatory hurdle.